Amber P van der Zalm
Overview
Explore the profile of Amber P van der Zalm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu D, van der Zalm A, Koster J, Bootsma S, Oyarce C, van Laarhoven H, et al.
Pharmacol Res
. 2024 Jul;
207:107315.
PMID: 39059615
Epithelial-mesenchymal transition (EMT) has been identified as a driver of therapy resistance, particularly in esophageal adenocarcinoma (EAC), where transforming growth factor beta (TGF-β) can induce this process. Inhibitors of TGF-β...
2.
van der Zalm A, Dings M, Manoukian P, Boersma H, Janssen R, Bailey P, et al.
Commun Med (Lond)
. 2024 May;
4(1):89.
PMID: 38760583
Background: Despite the advent of neoadjuvant chemoradiotherapy (CRT), overall survival rates of esophageal adenocarcinoma (EAC) remain low. A readily induced mesenchymal transition of EAC cells contributes to resistance to CRT....
3.
van der Zalm A, Bootsma S, Rodermond H, Oei A, Bijlsma M
STAR Protoc
. 2023 Feb;
4(1):102098.
PMID: 36825807
Severe combined immunodeficient mice are typically used for xenografting experiments and show reliable tumor engraftment; however, their Prkd mutation renders them highly sensitive to irradiation. Here, we describe a protocol...
4.
Dings M, van der Zalm A, Bootsma S, van Maanen T, Waasdorp C, Ende T, et al.
Cell Rep Med
. 2022 Nov;
3(11):100802.
PMID: 36334593
Neoadjuvant chemoradiotherapy (nCRT) improves outcomes in resectable esophageal adenocarcinoma (EAC), but acquired resistance precludes long-term efficacy. Here, we delineate these resistance mechanisms. RNA sequencing on matched patient samples obtained pre-and...
5.
Liu D, Steins A, Klaassen R, van der Zalm A, Bennink R, van Tienhoven G, et al.
Biomedicines
. 2020 Oct;
8(11).
PMID: 33105540
Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma and a hypoxic microenvironment. Pancreatic stellate cells (PSC) are activated by hypoxia and promote excessive desmoplasia, further contributing to the development...
6.
Steins A, van Mackelenbergh M, van der Zalm A, Klaassen R, Serrels B, Goris S, et al.
EMBO Rep
. 2020 Mar;
21(5):e48780.
PMID: 32173982
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundance of stroma. Multiple molecular classification efforts have identified a mesenchymal tumor subtype that is consistently characterized by high-grade growth and poor...
7.
Steins A, Ebbing E, Creemers A, van der Zalm A, Jibodh R, Waasdorp C, et al.
Int J Cancer
. 2019 Apr;
145(10):2792-2803.
PMID: 31018252
Multimodality treatment has advanced the outcome of esophageal adenocarcinoma (EAC), but overall survival remains poor. Therapeutic pressure activates effective resistance mechanisms and we characterized these mechanisms in response to the...
8.
Ebbing E, van der Zalm A, Steins A, Creemers A, Hermsen S, Rentenaar R, et al.
Proc Natl Acad Sci U S A
. 2019 Jan;
116(6):2237-2242.
PMID: 30670657
Esophageal adenocarcinoma (EAC) has a dismal prognosis, and survival benefits of recent multimodality treatments remain small. Cancer-associated fibroblasts (CAFs) are known to contribute to poor outcome by conferring therapy resistance...